### ü´† Cardiology: Transthyretin Gene Sequencing in Cardiac Amyloidosis

#### ‚úÖ True Statements
1. **Transthyretin (TTR) gene sequencing** differentiates **hereditary transthyretin (h‚ÄëATTR) cardiac amyloidosis** from **wild‚Äëtype transthyretin (wt‚ÄëATTR) amyloidosis**.
2. **Hereditary transthyretin (h‚ÄëATTR) amyloidosis** is caused by a **pathogenic variant** in the **TTR gene**, most commonly **Val122Ile**.
3. Detecting a **pathogenic TTR variant** permits **family risk stratification** because first‚Äëdegree relatives who carry the variant have an increased lifetime risk of **cardiac amyloidosis**.
4. **Wild‚Äëtype transthyretin (wt‚ÄëATTR) amyloidosis** is an **age‚Äërelated** process that accounts for approximately **10‚ÄØ%‚Äì15‚ÄØ% of heart failure cases in older adults**.
5. A **positive technetium‚Äë99m pyrophosphate cardiac scintigraphy** scan in the **absence of monoclonal light chains** is diagnostic for **ATTR cardiac amyloidosis**.
6. Evaluation for **light‚Äëchain (AL) amyloidosis** requires **serum and urine protein electrophoresis with immunofixation** and **free light‚Äëchain analysis**.
7. An **echocardiogram** showing **severe concentric left ventricular hypertrophy, biatrial enlargement, and multivalvular regurgitation** is characteristic of **cardiac amyloidosis**.
8. **Endomyocardial biopsy** is **not necessary** to diagnose **ATTR cardiac amyloidosis** when the non‚Äëinvasive imaging and laboratory findings are definitive.
9. **Bone marrow biopsy** identifies **plasma cell dyscrasias** associated with **AL amyloidosis** but is unnecessary when light‚Äëchain studies are normal.
10. **Coronary angiography** evaluates **coronary artery disease** in heart failure, but when echocardiography demonstrates amyloid‚Äëtypical findings, amyloidosis should be considered before ischemic causes.

#### üí¨ Extra
1. Differentiating h‚ÄëATTR from wt‚ÄëATTR guides therapy selection and eligibility for disease‚Äëmodifying agents.
2. The Val122Ile variant is especially prevalent in individuals of African ancestry.
3. Genetic counseling accompanies TTR sequencing so that at‚Äërisk relatives can undergo surveillance and early intervention.
4. wt‚ÄëATTR commonly presents in older men with **heart failure with preserved ejection fraction (HFpEF)** or bilateral carpal tunnel syndrome.
5. Grade‚ÄØ‚â•‚ÄØ2 radiotracer uptake on scintigraphy has >90‚ÄØ% specificity for ATTR amyloidosis when AL disease is excluded.
6. The combined sensitivity of serum and urine immunofixation plus free light‚Äëchain assay for AL amyloidosis exceeds 99‚ÄØ%.
7. The pattern of hypertrophy with preserved ejection fraction helps distinguish amyloidosis from hypertensive heart disease.
8. Biopsy is reserved for equivocal cases or enrollment in clinical trials.
9. Absence of a monoclonal protein essentially excludes systemic AL amyloidosis, making bone marrow evaluation low yield.
10. Ischemic evaluation is pursued when clinical suspicion for coronary artery disease remains high despite amyloid‚Äësuggestive imaging.

#### üî∑ Tags
#Cardiology #AmbulatoryCare #PatientOver65 #CardiacAmyloidosis #ATTR #GeneticTesting #HeartFailure

#### üìö Reference
Garcia‚ÄëPavia‚ÄØP, Rapezzi C, Adler Y, et‚ÄØal. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*. 2021;42:1554‚Äë1568. PMID:‚ÄØ33825853 doi:10.1093/eurheartj/ehab072

#### üÜî Question ID
CVMCQ24071

#### üïí Last Updated
February‚ÄØ2025

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Myocardial Disease, Cardiac Amyloidosis

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Cardiac amyloidosis** results from **deposition of misfolded proteins** within the myocardium, leading to **restrictive physiology** and **heart failure**.
2. **Cardiac amyloidosis** often presents with **normal left ventricular systolic function and cavity size**, but with **abnormal diastolic function**.
3. The two major types of **cardiac amyloidosis** are **immunoglobulin light-chain (AL) amyloidosis** and **transthyretin (ATTR) amyloidosis**.
4. **CMR imaging** is highly sensitive and specific for **cardiac amyloidosis** but does **not distinguish between AL and ATTR types**.
5. In the absence of **monoclonal light chains**, a **positive 99m-technetium pyrophosphate scintigraphy** scan is diagnostic of **ATTR amyloidosis**.
6. **AL amyloidosis** is a **multiorgan disease** associated with **plasma cell dyscrasias** and is diagnosed by biopsy and abnormal light chains.
7. **Endomyocardial biopsy** is not required if **extracardiac biopsy** and **CMR abnormalities** confirm cardiac involvement in **AL amyloidosis**.
8. **TTR gene sequencing** should be performed in patients with suspected **ATTR amyloidosis** to differentiate **hereditary (h-ATTR)** from **wild-type (wt-ATTR)** forms.
9. **Hereditary ATTR amyloidosis (h-ATTR)** is **autosomal dominant** and most commonly caused by a **Val122Ile variant**.
10. **Wild-type ATTR amyloidosis (wt-ATTR)** is an **age-related disorder** and accounts for up to **10‚Äì15% of heart failure cases in older adults**.
11. **Tafamidis** is an **FDA-approved therapy** for **ATTR cardiomyopathy**, shown to **reduce mortality and cardiovascular hospitalization**.
12. **Patisiran** and **inotersen**, which reduce **hepatic transthyretin production**, are approved for **ATTR polyneuropathy** and may benefit **ATTR cardiomyopathy**.
13. **Liver or combined heart-liver transplantation** may be considered in select patients with **hereditary ATTR amyloidosis**.

#### üí¨ Extra
1. Restrictive physiology results from **amyloid deposition** limiting diastolic filling.
2. Diastolic dysfunction contributes to **congestive symptoms** despite preserved ejection fraction.
4. Subtype differentiation is critical for directing **appropriate treatment and prognosis**.
5. **Dual testing** with monoclonal screen and bone scan enables **nonbiopsy diagnosis** of **ATTR cardiac amyloidosis**.
6. Light-chain amyloidosis requires **hematologic therapy**, not amyloid-targeted therapy alone.
9. The **Val122Ile variant** is particularly prevalent in **Black populations** in the United States.
11. Tafamidis stabilizes the **tetrameric structure** of transthyretin and prevents amyloidogenesis.

#### üî∑ Tags
#Cardiology #AmbulatoryCare #CardiacAmyloidosis #InfiltrativeCardiomyopathy #ECGFindings #LowVoltage #CMR #99mTcPyrophosphate #ATTR #ALAmyloidosis #Tafamidis #Transthyretin #HereditaryAmyloidosis #HeartFailure #HematologyOverlap

#### üìô Reference
MKSAP 19 Cardiovascular Medicine. American College of Physicians.

#### üÜî Question ID
CVVDX24007

#### üïí Last Updated
February 2025

---

#### üñºÔ∏è Supplemental Figures

<!--Subtypes of Cardiac Amyloidosis -->
<table>
  <caption><strong>Subtypes of Cardiac Amyloidosis</strong></caption>
  <thead>
    <tr>
      <th>Subtype</th>
      <th>Demographics</th>
      <th>Clinical Manifestations</th>
      <th>Diagnostic Tests</th>
      <th>Therapy</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>AL</td>
      <td>M ‚âà F, aged 40‚Äì80 y</td>
      <td>Nephrotic syndrome, cardiomyopathy, hepatosplenomegaly, neuropathy, carpal tunnel syndrome, bleeding diathesis, periorbital purpura, macroglossia</td>
      <td>
        Analysis for clonal plasma cell dyscrasias with SPEP, UPEP, serum/urine immunofixation, and serum FLC testing<br>
        Bone marrow biopsy<br>
        CMR imaging with LGE<br>
        Endomyocardial biopsy or other tissue biopsy
      </td>
      <td>
        Treatment of plasma cell dyscrasias<br>
        Cardiac transplantation in selected cases
      </td>
    </tr>
    <tr>
      <td>ATTR</td>
      <td>
        h-ATTR: M &gt;&gt; F, aged 55‚Äì75 y<br>
        wt-ATTR: M &gt;&gt;&gt; F, aged 65‚Äì95 y
      </td>
      <td>Cardiomyopathy, carpal tunnel syndrome, spinal stenosis, neuropathy</td>
      <td>
        CMR imaging with LGE<br>
        99m-Technetium pyrophosphate scintigraphy<br>
        Endomyocardial biopsy (controversial)<br>
        Genetic testing
      </td>
      <td>
        Tafamidis<br>
        Diflunisal (off label)<br>
        Patisiran (neuropathy)<br>
        Inotersen (neuropathy)<br>
        Liver or heart-liver transplantation
      </td>
    </tr>
  </tbody>
</table>
<p><em>
AL = amyloid light chain; ATTR = amyloid transthyretin; CMR = cardiac magnetic resonance; F = females; FLC = free light chain; h-ATTR = hereditary amyloid transthyretin; LGE = late gadolinium enhancement; M = males; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis; wt-ATTR = wild-type amyloid transthyretin.
</em></p>
<p>
Information from Witteles R. Cardiac amyloidosis. 
<a href="https://www.acc.org/latest-in-cardiology/articles/2016/07/07/14/59/cardiac-amyloidosis" target="_blank">
https://www.acc.org/latest-in-cardiology/articles/2016/07/07/14/59/cardiac-amyloidosis
</a>. Accessed September 4, 2024.
</p>

<!--99m-Technetium Pyrophosphate Scan in Hereditary ATTR Cardiac Amyloidosis -->
<figure>
  <img src="99mtcpyp_attr_amyloidosis.jpg" alt="99m-Technetium Pyrophosphate Scan in Hereditary ATTR Cardiac Amyloidosis">
  <figcaption>
    <strong>99m-Technetium Pyrophosphate Scan in a Patient With Hereditary Transthyretin Cardiac Amyloidosis</strong><br>
    Cardiac uptake of the radiotracer is denser than bone uptake at both 1 hour (top panel) and 3 hours (bottom panel).
  </figcaption>
</figure>